01/14/2022 | Press release | Distributed by Public on 01/14/2022 01:51
1. Title | Acquisition of Domestic Product License for Novavax COVID-19 Vaccine | |
2. Details |
1. Product name - NUVAXOVID Pre-filled Syringe (SARS-CoV-2 Spike Protein Vaccine(Recombinant)) 2. Target disease - Prevention for SARS-CoV-2 3. Date of license application(approval) of product and licensing authority - Application date : 2021.11.15 - Approval date : 2022.01.12 - Approval authority : Ministry of Food and Drug Safety (MFDS, Republic of Korea) 4. Expected effect - Recombinant SARS-CoV-2 antigen protein contained in this vaccine forms the antibodies against the SARS-CoV-2 virus inside the body and exhibits an immune response when exposed to the SARS-CoV-2, enabling prevention against COVID-19. 5. Future plans - Expected for domestic supply |
|
3. Date of board resolution (decision date) or confirmation date | 2022-01-12 | |
- Attendance of outside directors | Present(No.) | - |
Absent(No.) | - | |
- Attendance of auditors (members of Audit Committee who are not outside directors) | - | |
4. Other matters to be factored into investment decisions | ||
- The above product's codename is 'NVX-CoV2373'. - The above '3. Date of board resolution(decision date) or confirmation date' is the date of the approval. |
||
※ Related disclosure | - |